Dec. 19, 2011
/PRNewswire/ -- Pharmacyclics, Inc. (Nasdaq: PCYC), a biopharmaceutical company focused on developing and commercializing innovative small molecule drugs for the treatment of cancer and immune mediated diseases, announced today issue notification from the United States Patent & Trademark Office (USPTO,
) of a patent entitled "Inhibitors of Bruton's Tyrosine Kinase" and specifically claiming "an inhibited tyrosine kinase comprising an irreversible BTK inhibitor having a covalent bond to a cysteine residue of a Bruton's tyrosine kinase (BTK)". This U.S. patent 8,088,781 is set to issue on
"We are very pleased to announce to our stakeholders that the USPTO has granted us this patent, which further strengthens our BTK intellectual property portfolio and confirms Pharmacyclics as being the first in the BTK irreversible inhibitor space," said
, Chairman and CEO of Pharmacyclics. "I consider it an honor and recognition of the knowledge, skill, and innovation of the Pharmacyclics employees and other individuals who were involved in the creation of this intellectual property."
About BTK inhibitor, PCI-32765
PCI-32765 is a first-in-class oral, selective, irreversible BTK inhibitor, which Pharmacyclics is developing for the treatment of patients with B-cell malignancies. B-cell maturation is mediated by B-cell receptor (BCR) signal transduction and BTK is an essential part of the signaling pathway. Recent studies indicate that some B-cell lymphomas depend on chronic active signals from the BCR, and that suppression of this signaling by PCI-32765 can induce apoptosis and inhibit cell migration. Pharmacyclics is currently evaluating PCI-32765, in several Phase 2 clinical trials such as mantle cell lymphoma, chronic lymphocytic leukemia, diffuse large B-cell lymphoma, and multiple myeloma (for more information see
) and planning for Phase 3 in mid-2012.
Pharmacyclics® is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative small-molecule drugs for the treatment of cancer and immune mediated diseases. Our mission and goal is to build a viable biopharmaceutical company that designs, develops and commercializes novel therapies intended to improve quality of life, increase duration of life and resolve serious unmet medial healthcare needs; and to identify promising product candidates based on scientific development expertise, develop our products in a rapid, cost-efficient manner and pursue commercialization and/or development partners when and where appropriate.